The National Institutes of Health selected Lenzilumab for the COVID-19's Large Effect Trial (BET)

Humanigen, a clinical-phase biopharmaceutical company focused on the prevention and treatment of cytokine storms, announced that the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will select Humanigen's lenzilumab for A LARGE-effect test of COVID-19, a monoclonal antibody drug that targets cytomegalophaphacluster-concentration stimulation factors (GM-CSF).
BET will help advance NIAID's COVID-19 research strategic plan.
the trial, based on the initial data of NIAID's ACTT, showed that Gilead's antiviral drug remdesivir could improve the recovery time of COVID-19 inpatients.
BET will assess the effectiveness and safety of the lenzilumab and Redsiwe combinations with placebo and Redsiwe in inpatient SCOVID-19 patients.
expects the trial to recruit 100 patients in each branch of the study and conduct a mid-term efficacy analysis after recruiting 50 patients in each branch.
GM-CSF is a single-chain glycoprotein of 23 kDa that activates multiple signal transduction pathways by binding to heterogeneous dipolymer receptors on the surface of bone marrow cells.
.